Company: NIVFW
Filing Date: 2025-10-31
Form Type: 424B3
Source: 0001213900-25-104469
Chunk: 97

Company: NewGenIvf Group Ltd
Filing Date: 2025-10-31
Form: 424B3
Chunk 97
---
 NewGenIvf have limited or no prior experience; |

| ● | regulatory risks, including                                                                                                          
 remaining in good standing with existing regulatory bodies or receiving any necessary pre-closing or post-closing approvals, as well 
 as being subject to new regulators with oversight over an acquired business;                                                         |

| ● | assumption of contractual                                                                                                        
 obligations that contain terms that are not beneficial to NewGenIvf, require it to license or waive intellectual property rights 
 or increase its risk for liability;                                                                                              |

| ● | failure to further successfully  
 develop the acquired technology; |

| ● | liability for activities                                                                                                             
 of the acquired business before the acquisition, including intellectual property infringement claims, violations of laws, commercial 
 disputes, tax liabilities and other known and unknown liabilities;                                                                   |

| ● | potential disruptions to            
 NewGenIvf’s ongoing businesses; and |

| ● | unexpected costs and unknown                                                 
 risks and liabilities associated with strategic investments or acquisitions. |

Even if the transaction is
consummated, NewGenIvf may only have limited control over the companies in which it only has minority stake, it cannot ensure that these
companies will always comply with applicable laws and regulations in their business operations. Non-compliance of regulatory requirements
by NewGenIvf’s investees may cause substantial harm to NewGenIvf’s reputations and the value of NewGenIvf’s investment.
In addition, if the resulting business from such a transaction fails to meet NewGenIvf’s expectations, or it fails to successfully
integrate such businesses into its own, its business, financial condition and results of operations may be adversely affected or it may
be exposed to unknown risks or liabilities. If NewGenIvf is unable to effectively address these challenges, its ability to execute acquisitions
as a component of its long-term strategy will be impaired, which could have an adverse effect on its growth. As a result of the above,
NewGenIvf’s strategies may not be successfully implemented beyond the current markets.

Any investment might not
achieve the synergies, operational or financial benefits it expects and may adversely impact NewGenIvf’s operating results. In
addition, NewGenIvf cannot assure you that any future investment in or acquisition of new businesses or technology will lead to the successful
development of new or enhanced products and services or that any new or enhanced products and services, if developed, will achieve market
acceptance, or prove to be profitable.

<div align='center'>52</div>

Changes in